Last updated: July 20, 2026
ENDO USA, INC. v. GLAND PHARMA LIMITED (3:24-cv-11529): Litigation Summary, Patent Targets, and Current Risk to Generic Entry
ENDO USA, Inc. v. Gland Pharma Limited, docket 3:24-cv-11529, is a U.S. patent infringement action filed in federal court in 2024, targeting Gland Pharma’s proposed generic/ANDA entry for an Endo product. The case posture and actionable risk hinge on (1) which patents are listed in the Orange Book for the reference listed drug, (2) whether the complaint asserts infringement of composition, method-of-use, and/or formulation-manufacturing claims, and (3) whether the matter is tied to Paragraph IV certifications and a triggering ANDA filing date.
No litigation summary, claim construction snapshot, settlement status, or asserted-patent list can be produced from the docket identifier alone.
What court is 3:24-cv-11529 in, and what procedural stage is the case in?
A complete litigation summary requires docket facts: court division, judge, service status, schedule (answer, motions to dismiss, Markman/claim construction), and whether the matter is at the preliminary injunction stage. None of those elements are available from the case caption and number alone.
What patents are asserted in ENDO USA, INC. v. GLAND PHARMA LIMITED 3:24-cv-11529?
A defensible analysis requires the asserted patent numbers and claim sets, including whether Endo alleges infringement of:
- composition-of-matter
- formulation claims (e.g., solvate/polymorph, particle size, coating, stabilizers)
- manufacturing process claims
- method-of-use claims tied to specific dosing regimens
Is the case a Paragraph IV ANDA infringement action or something else?
Litigation that follows an ANDA generally maps to a Paragraph IV certification to listed patents and is tightly linked to ANDA submission timing and FDA acceptance dates. Without the complaint’s Paragraph IV details, the linkage cannot be stated.
What is the Orange Book status for the Endo drug at issue, and which listed patents drive the suit?
A litigation-impact analysis depends on:
- which patents appear in the Orange Book for the specific reference product
- their expiration dates
- whether any are listed as “method of use” or “exclusivity expiring by statute”
- whether any are already expired or under terminal disclaimers
Those facts require the Orange Book listing for the specific Endo product referenced in the complaint.
Patent estate and generic entry risk: How strong is Endo’s case in 3:24-cv-11529?
A standard strength assessment for ANDA litigation depends on:
- number of asserted patents and claim types
- claim overlap with common generic design-arounds
- whether the patents are “core” (composition) versus “peripheral” (formulation tweaks)
- litigation history of the asserted patents (prior validity/infringement decisions)
- whether the case involves willfulness, infringement theories tied to manufacturing controls, or labeling method-of-use provisions
The asserted-patent list, claim coverage, and technical infringement contentions are not available from the provided docket identifier.
Timeline framework: When would generic launch be blocked or enabled based on exclusivity and patent expiry?
To translate the litigation into launch risk, the analysis needs the exact reference product, listed patents, and any FDA exclusivity codes. A generic entry decision can turn on:
- earliest non-expired patent
- pediatric exclusivity extensions
- 180-day exclusivity to Paragraph IV challengers
- stay events tied to FDA approvals and 30-month timing rules
No such input is present.
Paragraph IV challenges and biosimilar risk: Does this matter implicate biologics-style exclusivity or only ANDA-style risks?
If the Endo product is small molecule, the framework is ANDA and Orange Book patents. If it is a complex drug product, there can be additional device, bridging, or REMS-related constraints. The case caption does not identify the therapeutic category, dosage form, or regulatory pathway.
How does Gland Pharma’s technology typically design around Endo’s patents, and what technical barriers matter?
Technical barriers in ANDA cases include:
- proving equivalence under relevant dissolution or release profiles
- meeting stability or particle-size controls tied to formulation patents
- satisfying process parameters that are mapped to process claims
A design-around analysis requires the infringement allegations and the generic product description from the complaint.
What settlement terms are common in Endo-style ANDA matters, and how would they affect market entry?
Settlement outcomes can include:
- early launch on “carve-out” labels or strengths
- delayed launch with payment
- covenant-not-to-sue while Gland pursues reformulation
- licensing of certain claims
A settlement cannot be characterized without the docket’s termination, consent judgment, or public notice history tied to 3:24-cv-11529.
Key Takeaways
- Case-specific litigation analysis cannot be completed from the docket number alone. A credible summary requires asserted-patent identification, court posture, and FDA/Orange Book linkage.
- Actionable generic entry risk is patent-driven. Without the Orange Book patents asserted in 3:24-cv-11529, no launch blocking or design-around strength assessment can be stated.
FAQs
- What information in the complaint determines whether ENDO USA v. Gland Pharma is a Paragraph IV ANDA case?
- Which Orange Book patents typically survive longest in Endo small-molecule litigation, and how are they used in infringement theories?
- How do courts handle obviousness and claim construction disputes in Hatch-Waxman patent infringement cases like 3:24-cv-11529?
- What docket events indicate a settlement or consent judgment in ANDA infringement litigation?
- How does FDA’s 30-month stay interact with patent expiry and 180-day exclusivity in Hatch-Waxman cases?
References
- No sources were provided or cited.
